title: Molecular Imaging and Precision Medicine in Lung Cancer.
abstract: Precision medicine allows tailoring of preventive or therapeutic interventions to avoid the expense and toxicity of futile treatment given to those who will not respond. Lung cancer is a heterogeneous disease functionally and morphologically. PET is a sensitive molecular imaging technique with a major role in the precision medicine algorithm of patients with lung cancer. It contributes to the precision medicine of lung neoplasia by interrogating tumor heterogeneity throughout the body. It provides anatomofunctional insight during diagnosis, staging, and restaging of the disease. It is a biomarker of tumoral heterogeneity that helps direct selection of the most appropriate treatment, the prediction of early response to cytotoxic and cytostatic therapies, and is a prognostic biomarker in patients with lung cancer.
authors.affiliation: Division of Nuclear Medicine and Molecular Imaging, Department of Medicine, McMaster University, 1200 Main Street West, Hamilton, Ontario L9G 4X5, Canada; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, McMaster University, 1200 Main Street West, Hamilton, Ontario L9G 4X5, Canada.
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Zukotynski
authors.affiliation: Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. Electronic address: gerbaudo@bwh.harvard.edu.
authors.forename: Victor H
authors.initials: VH
authors.lastname: Gerbaudo
mesh_terms: D014408:Biomarkers, Tumor; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy*; D057054:Molecular Imaging; D058990:Molecular Targeted Therapy; D049268:Positron-Emission Tomography / Q000379:methods*; D057285:Precision Medicine; D011237:Predictive Value of Tests; D011379:Prognosis; D019275:Radiopharmaceuticals
chemical_list: D014408:Biomarkers, Tumor; D019275:Radiopharmaceuticals
keywords: Cancer staging; Lung cancer; Positron emission tomography; Precision medicine; Solitary pulmonary nodule; Targeted cancer therapy